Abcodia Ltd is a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer. The Company’s first product is the ROCA© Test for the early detection of ovarian cancer, and it is expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia’s offerings are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed. The company maintains exclusive commercial access to a biobank of five million serum samples donated from more than 200,000 individuals over a 10-year period and holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. Headquartered in Cambridge, U.K., the Company has operations in Boston, Mass. and a clinical laboratory in Memphis, Tenn.
Latest funding size
Time since last funding
|over 1 year|
|Creandum, Scottish Equity Partners (SEP), Albion Ventures, Cambridge Innovation Capital, UCLB|